Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy ...

Pulmonary Fibrosis Awareness Month may be coming to a close, but it's important to keep the momentum going, columnist Sam Kirton says.

Aileron Therapeutics, Inc. ("Aileron") (NASDAQ: ALRN), a biopharmaceutical company advancing a novel pipeline of ...

Clinical trial results shared by Boehringer Ingelheim and Insilico Medicine showed improvement in idiopathic pulmonary ...

A University of Colorado professor won the 2024 Alton Ochsner Award for his work on disease risk factors for idiopathic ...

MHRA and HREC authorization in Australia further expands and will potentially accelerate enrollment in ongoing U.S. and UK Phase 2a biomarker ...

Aileron Therapeutics completes patient enrollment in Cohort 2 of phase 1b trial of LTI-03 in idiopathic pulmonary fibrosis: Austin, Texas Wednesday, September 25, 2024, 15:00 Hrs ...

A new statistical technique developed by a researcher at the Texas A&M University School of Public Health and colleagues ...

Interstitial Lung Disease (ILD) is a chronic condition marked by lung inflammation and scarring that makes breathing ...

Desaturation during the 6-minute walk test is a significant predictive factor for mortality in patients with idiopathic pulmonary fibrosis.

In this continuation of my last article, we will explore these challenges, the opportunities they present and the future ...

The most common breast cancer is HER2-negative, so called because it has low amounts of one of the proteins that contribute to tumor cell growth, HER2. Despite this common trait, the development of ...